Cardiff Oncology - 53 Year Dividend History | CRDF

Historical dividend payout and yield for Cardiff Oncology (CRDF) since 1971. The current TTM dividend payout for Cardiff Oncology (CRDF) as of May 17, 2024 is $0.00. The current dividend yield for Cardiff Oncology as of May 17, 2024 is 0.00%.
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.167B $0.000B
Cardiff Oncology Inc. is a clinical-stage biotechnology company. It engages in developing treatment for cancer patients. The company's product pipeline consists of a Phase 1b/2 study of onvansertib in combination with FOLFIRI/Avastin(R) in KRAS-mutated metastatic colorectal cancer; a Phase 2 study of onvansertib in combination with Zytiga(R) in Zytiga-resistant metastatic castration-resistant prostate cancer; and a Phase 2 study of onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia. Cardiff Oncology Inc., formerly known as Trovagene Inc., is based in SAN DIEGO.
Stock Name Country Market Cap PE Ratio